泰格医药
(300347)
| 流通市值：304.68亿 | | | 总市值：463.32亿 |
| 流通股本：5.66亿 | | | 总股本：8.61亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 3,707,560,174.2 | 1,801,473,935.03 | 6,832,800,615.35 | 5,025,868,260.75 |
| 营业总成本 | 3,348,891,613.17 | 1,644,573,250.45 | 6,312,645,254.48 | 4,559,527,495.2 |
| 其他经营收益 | | | | |
| 营业利润 | -78,648,748.89 | 405,838,528.23 | 1,009,419,969 | 1,229,009,491.51 |
| 利润总额 | -80,215,307.94 | 405,944,308.45 | 1,003,215,119.99 | 1,222,780,755.26 |
| 净利润 | -185,471,319.77 | 330,083,645.62 | 805,056,174.52 | 1,091,681,166.46 |
| 每股收益 | | | | |
| 其他综合收益 | -176,529,004.82 | -87,366,018.26 | -53,653,137.05 | 9,646,423.79 |
| 综合收益总额 | -362,000,324.59 | 242,717,627.36 | 751,403,037.47 | 1,101,327,590.25 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 6,608,333,962.98 | 6,629,249,323.65 | 6,177,196,741.89 | 6,350,600,808.17 |
| 非流动资产: | | | | |
| 非流动资产合计 | 21,284,860,526.57 | 22,171,235,477.15 | 22,181,598,416.28 | 22,433,650,978.72 |
| 资产总计 | 27,893,194,489.55 | 28,800,484,800.8 | 28,358,795,158.17 | 28,784,251,786.89 |
| 流动负债: | | | | |
| 流动负债合计 | 2,658,743,846.48 | 2,879,679,287.51 | 2,835,474,052.17 | 2,937,853,013.04 |
| 非流动负债: | | | | |
| 非流动负债合计 | 2,142,884,678 | 1,355,885,340.22 | 1,266,895,915.05 | 1,138,805,470.53 |
| 负债合计 | 4,801,628,524.48 | 4,235,564,627.73 | 4,102,369,967.22 | 4,076,658,483.57 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 19,477,217,580.62 | 20,916,402,606.45 | 20,959,506,514.77 | 21,176,338,660.5 |
| 股东权益合计 | 23,091,565,965.07 | 24,564,920,173.07 | 24,256,425,190.95 | 24,707,593,303.32 |
| 负债和股东权益合计 | 27,893,194,489.55 | 28,800,484,800.8 | 28,358,795,158.17 | 28,784,251,786.89 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 4,182,554,947.92 | 2,090,446,149.88 | 7,371,765,963.04 | 5,414,289,272.77 |
| 经营活动现金流出小计 | 3,756,772,612.63 | 1,772,742,373.52 | 6,253,681,192.5 | 4,674,731,643.2 |
| 经营活动产生的现金流量净额 | 425,782,335.29 | 317,703,776.36 | 1,118,084,770.54 | 739,557,629.57 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,110,906,718.43 | 472,514,032.77 | 2,903,502,466.77 | 1,962,639,120.81 |
| 投资活动现金流出小计 | 1,062,094,433.42 | 418,277,776.93 | 2,411,945,914.54 | 1,468,932,322.79 |
| 投资活动产生的现金流量净额 | 48,812,285.01 | 54,236,255.84 | 491,556,552.23 | 493,706,798.02 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,339,034,826.47 | 348,864,549.16 | 1,422,094,305.84 | 1,268,284,871.59 |
| 筹资活动现金流出小计 | 1,469,614,084.88 | 341,289,381.07 | 3,348,779,515.36 | 2,953,073,235.54 |
| 筹资活动产生的现金流量净额 | -130,579,258.41 | 7,575,168.09 | -1,926,685,209.52 | -1,684,788,363.95 |
| 汇率变动对现金及现金等价物的影响 | -23,544,743.26 | -14,454,893.77 | -8,841,588.41 | 2,935,487.08 |
| 现金及现金等价物净增加额 | 320,470,618.63 | 365,060,306.52 | -325,885,475.16 | -448,588,449.28 |
| 期末现金及现金等价物余额 | 2,043,078,996.31 | 2,087,668,684.2 | 1,722,608,377.68 | 1,599,905,403.56 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 320,470,618.63 | - | -325,885,475.16 | - |
最新报告期：2026-08-31| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 浙商证券 | 郭双喜 | 0.40 | 1.48 | 1.93 | 2026-08-31 |
| 招商证券 | 梁广楷,许菲菲 | 0.82 | 1.83 | 2.66 | 2026-08-30 |